Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of olanzapine for the treatment of nausea and vomiting in palliative cancer care

Conditions: Nausea; Vomiting; End Stage Cancer

Summary: oral olanzapine showed superior antiemetic efficacy to metoclopramide as rescue treatment to control breakthrough emesis induced by chemotherapy. this study aims to evaluate safety and efficacy of olanzapine for nausea and vomiting in advanced cancer patients.

this will be a pilot study; open-label prospective clinical trial. oral olanzapine 5 mg tablet will be given to patients who fail two standard treatment medications for nausea and vomiting within 30 minutes after the first vomiting episode. other doses of olanzapine will be given at 12, 24, and 36 hours following the first dose concurrently with standard regimen. patients with emesis will be followed up after receiving olanzapine every 12 hour for 48 hours. we will record the frequency of vomiting, nausea, and retching.

Eligibility criteria:
inclusion criteria: 1. age 18-65 years. 2. diagnosis of advanced malignancy. 3. failed two standard medications for nausea/vomiting (after 6 hours from last dose). 4. adequate organ function, including the following: 1. hepatic: bilirubin ≤1.5 times the upper limit of normal (x uln); aspartate aminotransferase (ast), and alanine aminotransferase (alt) ≤3.0 x uln (ast, and alt ≤5 x uln is acceptable if liver has tumor involvement), alkaline phosphatase (ap) ≤5.0 x uln. 2. renal: calculated creatinine clearance (crcl) ≥30 ml/min based on the original weight based cockcroft and gault formula. 5. expected life expectancy \> 1 month. 6. patients must be able to read thai. 7. patients must sign an informed consent document. exclusion criteria: 1. patients with history of abdominal radiotherapy. 2. patients who receive chemotherapy within 1 week. 3. patients who take fluoxetine. 4. patients with heart failure or myocardial infarction in the past 6 months. 5. patients with qtc prolongation from baseline ecg. 6. known hypersensitivity to olanzapine. 7. patients who are unwilling to participate in the study.
a study to evaluate the safety and effectiveness of different doses of chrysalin in adults who have a broken wrist

Conditions: Radius Fracture

Summary: the purpose of this study is to evaluate the safety of chrysalin, also known as tp508, and to determine the effectiveness of four doses of chrysalin for treating broken wrists in adults.

there is a medical need for a product that is safe and can accelerate the rate of bone healing, leading to a reduction in immobilization time. chrysalin, also known as tp508, is a synthetic peptide (protein) that is an exact copy of part of the human protein thrombin, which is a protein that occurs naturally in the body. chrysalin can be used to mimic part of the thrombin response after injury without stimulating any of the events associated with blood clotting, and can therefore accelerate the normal process of healing.

Eligibility criteria:
inclusion criteria: * an unstable and/or displaced fracture of the distal radius * fracture classified as primary intra-articular or extra-articular * male, or non-pregnant, non-lactating female at least 18 years old. if female of childbearing potential, must have confirmed negative pregnancy test prior to administration of study product. must agree to use a medically approved method of birth control for 6 months. * need ability to understand study requirements, provide written informed consent, and comply with study protocol * need ability to understand and provide written authorization for use and disclosure of health information per health insurance portability and accountability act (hipaa) exclusion criteria: * history of distal radius fracture of the affected limb 2 years prior to study enrollment * history of uncontrolled type i or type ii diabetes mellitus * history or clinical evidence of any active medical disease or condition which would make the subject, in the opinion of the investigator, unsuitable for the study, or could potentially confound the results of the study * concurrent use of other investigational (non-food and drug administration \[fda\]-approved) agent or device * participation in any other clinical study within 90 days prior to treatment with the study drug * female subjects who are pregnant or nursing

Keywords: chrysalin tp508 fracture wrist healing
a study to evaluate the safety and tolerability of a nasal spray to treat perennial allergic rhinitis

Conditions: Perennial Allergic Rhinitis

Summary: the purpose of this study is to determine if one allergy treatment (0.15% azelastine hydrochloride) is as safe as mometasone furoate (nasonex) alone.


Eligibility criteria:
inclusion criteria: * male and female patients 12 years and older with a compatible history greater than or equal to 1 year of rhinitis due to perennial allergies. * must be willing and able to provide informed consent and to participate in all study procedures * must be in generally good health * positive skin test to a prevalent perennial allergen exclusion criteria: * on nasal examination, the presence of nasal mucosal erosion, nasal ulceration or nasal septal perforation * use of any investigational drug within 30 days of the first visit * any nasal surgery or sinus surgery within the previous year * presence of any hypersensitivity to drugs similar to azelastine or mometasone furoate and to either sorbital or sucralose * women who are pregnant or nursing * women who are not using an acceptable method of birth control * nasal diseases likely to affect deposition of intranasal medication, such as sinusitis, rhinitis medicamentosa or clinically significant nasal polyposis or nasal structural abnormalities. * asthma or other lung diseases such as copd. mild asthma symptoms may be considered after consultation with investigator. * patients with arrythmia * patients with know history of alcohol and drug abuse * existence of any surgical or medical condition, which in the opinion of the investigator or sponsor, might significantly alter the evaluation of the study. * use of medications that could affect the study results
characteristics of intensity and dependence to physical activity in anorexia nervosa

Conditions: Anorexia Nervosa

Summary: etude d'épidémiologie clinique multicentrique (imm), naturalistique, comparant un échantillon clinique à un échantillon de témoins issus de la population générale. cette recherche se fixe pour objectif principal de déterminer, sur un large échantillon de patients pris en charge pour anorexie mentale dans des unités de soins spécialisées, les caractéristiques de l'activité physique et la dépendance à l'exercice physique en comparaison avec des sujets issus de la population générale appariés pour l'âge et le sexe. nous faisons l'hypothèse que les patients anorexiques mentaux sont plus actifs et plus dépendants à l'exercice physique que des sujets de la population générale de même âge et de même sexe.


Eligibility criteria:
inclusion criteria: * sujets de sexe masculin et féminin, âgés entre 13 et 23 ans. * donnant leur consentement éclairé (et celui des parents pour les mineurs) * pour l'échantillon clinique : prise en charge pour anorexie mentale (selon les critères dsm-iv) dans le département de psychiatrie de l'enfant et de l'adolescent de l'institut mutualiste montsouris. * pour l'échantillon témoin : sujets issus de la population générale (collégiens lycéens étudiants). exclusion criteria: * personnes refusant la recherche * personnes souffrant d'une condition médicale majeure ou d'une invalidité.
neoadjuvant fluzoparib in germline brca-mutated three-negative breast cancer breast cancer

Conditions: TNBC - Triple-Negative Breast Cancer

Summary: although many parp inhibitors did not improve pcr in neoadjuvant studies, it is not an unchallenged conclusion that tnbc does not benefit from use of parp inhibitors in neoadjuvant therapy.this study is an open-label, two-cohort, multicenter trial. 60 patients with germline brca-mutated three-negative early breast cancer are planned to be enrolled and treated with fluzoparib combined with chemotherapy according to tumor response after ec (epirubicin and cyclophosphamide) for 2 cycles.


Eligibility criteria:
inclusion criteria: 1. women ≥ 18 and ≤ 70 years of age with treatment-naïve breast cancer 2. histopathologically confirmed early or locally advanced three-negative invasive breast cancer as defined by the asco/cap guidelines while meeting the following conditions: her2 negative: ihc 0/1 + or ihc2 + but ish negative; er and/or pr negative (not eligible for endocrine therapy): ihc nuclear staining ≤ 1% 3. tumor stage: ii-iii: primary tumor size: ≥ 2cm 4. ecog score 0 \~ 1; 5. centrally confirmed brca1 or brca2 germline mutation; 6. eligible level of organ function exclusion criteria: 1. patients with metastatic breast cancer or bilateral breast cancer or inflammatory breast cancer; 2. participated in other drug trials or received any anti-tumor therapy within 4 weeks before enrollment, including endocrine therapy, immunotherapy, biological therapy or tumor embolization; 3. previously received parpi therapy; 4. history of another primary malignancy; 5. confirmed history of heart failure or systolic dysfunction (lvef \< 50%); high risk uncontrolled cardiac arrhythmias, such as atrial tachycardia; 6. female patients who are pregnant or lactating; 7. history of allergy to drugs in this study；

Keywords: three-negative breast cancer with germline brca-mutated
lyon sarcoid uveitis cohort

Conditions: Sarcoid Uveitis

Summary: sarcoidosis is a systemic disease with unknown etiology. chronicity of the disease is observed in 1/3 of cases. five percent of the affected patients are expected to die due to pulmonary worsening. after pulmonary complications, ocular complications are one of the most frequent complications. in hospital setting 2 to 15% of patients who come for initial uveitis diagnosis are after examination due to sarcoidosis. sarcoidosis diagnosis is based on paraclinical exams (biological, radiography) and histological confirmation. corticotherapy (local or general) is usually used to cure sarcoid uveitis. in case of failure immunosuppressor or anti-tumor necrosis factor (tnf) can be used. in 10% of cases ocular symptoms including blindness are observed. only treatment administrated quickly after diagnosis of sarcoid uveitis can prevent from ophthalmologic complications. the main objective of the lyon sarcoid uveitis cohort study is to analyze the relevance of the paraclinical exam for sarcoid uveitis diagnosis, and to define a better visual and extra-ophthalmologic prognosis and describe the therapeutic practice in our department. this study is proposed to all patients diagnosed with sarcoid uveitis with a histological confirmation and referred to the internal medicine department of the croix-rousse hospital, lyon, france, for etiologic diagnosis or treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of sarcoid uveitis * first consultation in the department of internal medicine at the croix-rousse hospital, lyon, france exclusion criteria: * none
metformin as a chemoprevention agent in non-small cell lung cancer

Conditions: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung

Summary: the purpose of this study is to learn whether it is better to receive the drug metformin with standard of care for lung cancer or just standard of care.

participants will need to be scheduled to undergo a surgical resection of their lung cancer at the mayo clinic in rochester, minnesota. they will be asked to provide a blood sample prior to their surgery. samples of tumor tissue and normal lung tissue will be taken from the samples removed during your lung surgery. the tissue will be used to evaluate dna. a skin biopsy at the edge of the incision that has already been made will be done during your surgery. we will take the skin and grow skin fibroblasts. then we will reprogram the skin fibroblasts into induced pluripotent cells. you will be "randomized" into one of the study groups to either take metformin for 6 months with your standard of care follow up or to receive standard of care follow up.

Eligibility criteria:
inclusion criteria * suspected or biopsy proven stage ia-iiia lung squamous cell carcinoma (scc) (must be proven scc at the time of surgery) * medically fit for surgical resection (based on surgeon assessment) * current or prior smoker * age \> 18 years old * both male and female * willing and able to consent to study, undergo study interventions, and take study drug * eastern cooperative oncology group (ecog) performance status 0, 1, 2 * subject must start metformin within 90 days of surgery. exclusion criteria * currently taking metformin or other diabetic drugs * current or previous congestive heart failure, renal failure or liver failure * creatinine in women of 1.4 or greater and creatinine in men of 1.5 or greater * existing untreated or prior cancer \<5 years from diagnosis * received neo-adjuvant platinum-based chemotherapy or targeted therapy * receiving adjuvant platinum-based chemotherapy or targeted therapy after surgical resection

Keywords: bronchoscopy metformin
the oral symptom assessment scale in older patients with frailty

Conditions: Frailty; Older Adults

Summary: oral (or mouth) symptoms are common in older patients who live with frailty. it is known that frailty describes someone's overall resilience and how this relates to the chances of recovery following a health problem. a questionnaire called the oral symptom assessment scale (or osas) was designed to look at mouth symptoms in patients who had an advanced cancer. these symptoms may overlap with patients who have frailty. this research study is taking place to find out if the osas will be a suitable questionnaire that can be used in older patients with frailty. this study will take place in our lady's hospice \& care services, harold's cross and st james' hospital over six months.

participants will be asked by one of our researchers about the presence or absence of 21 mouth symptoms in the last week. if present, the participant will be asked about how bothersome each symptom is as well as the severity and frequency. up to three additional mouth symptoms that are not listed in the osas can be reported and rated in the same way by the participant. participants will be asked about the questionnaire itself to provide feedback. this will take approximately 10-15 minutes to complete both.

Eligibility criteria:
inclusion criteria * age ≥ 65 years old * clinical frailty score ≥ 5 * no known history of dementia * the attending clinician should have no concerns about a participant's capacity to consent for this research exclusion criteria: * inability to provide informed consent * inability to complete the questionnaire * abbreviated mental test score -4 (amt4) \<4

Keywords: frailty mouth symptom assessment aged
minimal invasive autopsies to investigate changes in deceased covid-19 patients

Conditions: COVID-19

Summary: rationale in a very short time corona virus disease 2019 (covid-19) has become a pandemic with high morbidity and mortality. the main cause of death is respiratory failure including acute respiratory distress syndrome, however the exact mechanisms and other underlying pathology is currently not yet known. in the current setting of the covid-19 pandemic complete autopsies seem too risky due to the risk of sars cov-2 transmission. yet, as so little is known, additional histopathological, microbiological and virologic study of tissue of deceased covid-19 patients will provide important clinical and pathophysiological information. minimal invasive autopsy combined with postmortem imaging seems therefore an optimal method combining safety on the one hand yet proving significant information on the other. this study aims to determine the cause of death and attributable conditions in deceased covid-19 patients. this will be performed using post-mortem ct-scanning plus ct-guided mia to obtain tissue for further histological, microbiological and pathological diagnostics. in addition, the pathophysiology of covid-19 will be examined by further tissue analysis.


Eligibility criteria:
inclusion criteria: * all patients with covid-19 that die during hospitalization in jessa hospital. covid-19 is defined as either a positive sars cov-2 pcr result or a high clinical suspicion combined with typical radiologic findings in the absence of an alternative explanation for the clinical picture. exclusion criteria: * none

Keywords: covid-19 cause of death pathophysiology
effects of chromium on insulin resistance in alzheimer disease patients

Conditions: Alzheimer Disease

Summary: the effect of chromium to improve glucose levels in alzheimer disease (ad) is controversial. the hypothesis of the study is to evaluate the effect of supplementing the ad individuals with chromium combined with exercise and assessing the effect of the supplementation on glucose metabolism.

chromium is an essential nutrient required for optimal insulin activity and normal carbohydrate and lipid metabolism. beyond its nutritional effects, dietary supplement of chromium causes beneficial outcomes against several diseases, in particular diabetes-associated complications such as alzheimer disease. common forms include chromium chloride, chromium nicotinate, and chromium picolinate. the argument for chromium supplementation relies on evidence from case reports of resolution of diabetic symptoms refractory to insulin via chromium added to total parenteral nutrition, and experiments in which animals deficient in chromium exhibited impaired glucose metabolism. chromium may influence glucose metabolism by increasing the number of insulin receptors or by binding insulin to receptors. the us food and drug administration concludes that, based on recent studies, chromium picolinate may reduce the risk of insulin resistance and therefore may reduce the risk of type 2 diabetes. a number of systematic reviews and meta-analyses have been conducted to determine the effect of chromium on glycemic control, although large, quality trials are limited. the majority of studies have found no effect on measured outcomes, with a few studies contributing to the positive observed effects. variations of preparations used in the trials and study conditions make generalization of the results difficult. in order to provide a comprehensive clinical evaluation of the effects of chromium in ad patients, we will conduct a double-blinded and placebo-controlled trial in subjects with ad.

Eligibility criteria:
inclusion criteria: * outpatients with a diagnosis of alzheimer's disease. * exhibiting an onset and progression of cognitive dysfunction during at least 3 months prior to the screening period. exclusion criteria: * patients with neurodegenerative diseases other than alzheimer's disease. * patients with cognitive dysfunction due to cerebral damage resulting from a lack of oxygen, a brain injury, etc. * patients with clinically significant cardiovascular disease. * patients with history of clinically-evident stroke. * patients with history of cancer in the last 5 years. * patients with clinically-significant systemic illness that may affect safety or completion of the study.
post-market registry of the acist cpm system and navvus catheter in clinical practice

Conditions: Coronary Artery Disease

Summary: this registry will collect real-world clinical evidence on the performance, safety, and usability of the acist cpm system and navvus catheter when used in accordance with approved labeling in a european commercial setting. up to 60 subjects will have fractional flow reserve (ffr) measurements of coronary lesions attempted with the cpm system and navvus catheter. all subjects will receive diagnostic treatment according to clinical indications and center standard practice.

there are no protocol-specific procedural requirements for this registry. enrolled subjects will undergo a diagnostic angiography procedure including an ffr measurement with the cpm system and navvus catheter according to the center standard of care and the instructions for use of the cpm system and navvus catheter. participants will be followed for the duration of hospital stay, an expected average of 1 day.

Eligibility criteria:
inclusion criteria: * subjects 18 years of age or older in whom ffr measurement is indicated to guide percutaneous coronary intervention (pci) strategy and use of the acist cpm system and navvus catheter is attempted. exclusion criteria: -

Keywords: fractional flow reserve rapid exchange catheter
plaquenil for alopecia areata, alopecia totalis

Conditions: Alopecia Areata

Summary: alopecia areata is an autoimmune condition resulting in hair loss and complete baldness (alopecia totalis). published evidence says that it is mediated by t-lymphocytes. plaquenil is an anti-inflammatory drug approved by the fda for malaria, lupus erythematosus, and rheumatoid arthritis. it has an effect on t-lymphocyte mediated inflammation, making it a logical choice for a treatment trail for alopecia areata.

alopecia areata is a high prevalence autoimmune disease with significant consequences. alopecia areata is a tissue restricted autoimmune disease directed at the hair follicle, resulting in hair loss. patients frequently suffer severe psychiatric consequences. this is especially true of girls and young women who become bald. the incidence of alopecia areata in the usa (minnesota is 20.2 per 100,000 person-years with a lifetime risk of approximately 1.7%. there is no significant gender difference. the disease is often chronic with a remitting, relapsing course. although it responds to immunosuppression, generalized immunosuppression has significant morbidity and treatment is frequently frustrating and not successful. new treatment options are essential. with evidence that alopecia areata is a t-lymphocyte mediated autoimmune condition it has become a model system for the study of pathogenesis and treatment of t-cell mediated autoimmunity and as such is a model for a host of additional t-cell mediated autoimmune conditions.

Eligibility criteria:
inclusion criteria: 1. severe alopecia areata: \>75% loss of scalp hair or alopecia areata totalis: 100% loss of scalp hair above with or without loss of body hair (alopecia universalis) 2. group i (8 subjects): duration of disease less than 1 year 3. group ii (8 subjects): duration of disease greater than 1 year 4. at least 18 years old 5. able to give consent. exclusion criteria: 1. coexisting significant systemic disease that would increase risk of hydroxychloroquine (e.g. renal disease, liver disease, alcoholism, anemia, blood dyscrasia, psoriasis, porphyria) 2. systemic immunosuppressive therapy within 3 weeks (e.g. prednisone, cyclosporin, azathioprine) 3. immunosuppressive conditions (e.g. hiv infection, cancer immunotherapy genetic immunodeficiency 4. medications with potential interaction to hydroxychloroquine (e.g. liver toxins, bone marrow toxins) 5. pregnancy, or breast feeding 6. women of child bearing potential not able or willing to use two methods of contraception at least one of which is not a hypersensitivity to 4-aminoquinolone compounds (chloroquine and hydroxychloroquine) 9. glucose-6-phosphate deficiency.

Keywords: treatment of alopecia areata